Patricia Pautier, MD, discusses the rationale for the phase 2 LMS-02 trial in uterine and soft tissue leiomyosarcoma.
Patricia Pautier, MD, head of the Medical Day Hospital Unit at the Institut Gustave Roussy Cancer Campus, discusses the rationale for the phase 2 LMS-02 trial in uterine and soft tissue leiomyosarcoma.
Soft tissue sarcomas are rare and relatively heterogeneous malignancies, Pautier explains. Some subtypes, such as leiomyosarcoma, are associated with poor prognosis and therefore, have limited studies dedicated to them.
The LMS-02 trial evaluated the safety and efficacy of doxorubicin in combination with trabectedin in patients with metastatic or advanced uterine and soft tissue leiomyosarcoma.
To date, the first-line standard of care for this patient population is doxorubicin alone, Pautier concludes.